“…In the first case, transparency of HTA bodies, the very operation of the appraisal body, the Transparency Council (TC), has been a major improvement in the area of transparency (Kolasa et al ., 2011b). Nevertheless, the AHTAPol has faced challenges in ensuring the transparency of its relationships with key stakeholders in the drug evaluation process, especially policymakers (Nizankowski and Wilk, 2009) and drug manufacturers (Kolasa et al ., 2011b; Ozierański et al ., 2012a, 2012b, Ozierański and King, 2017), although, of course, these problems are not unique to Poland. Similar findings have been reported in other EU countries, especially in CEE (Franken et al ., 2012; Gulácsi et al ., 2014).…”